uniQure
uniQure
QURE
NASDAQ
12.91
USD
-3.22%
About
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies.
It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study.
AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 492.5K |
| Three Month Average Volume | 60.5M |
| High Low | |
| Fifty-Two Week High | 11.35 USD |
| Fifty-Two Week Low | 3.73 USD |
| Fifty-Two Week High Date | 10 Jul 2024 |
| Fifty-Two Week Low Date | 05 Jul 2024 |
| Price and Volume | |
| Current Price | 5.85 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -24.25% |
| Thirteen Week Relative Price Change | 10.42% |
| Twenty-Six Week Relative Price Change | -4.82% |
| Fifty-Two Week Relative Price Change | -46.40% |
| Year-to-Date Relative Price Change | -27.03% |
| Price Change | |
| One Day Price Change | -5.95% |
| Thirteen Week Price Change | 18.18% |
| Twenty-Six Week Price Change | 4.65% |
| Five Day Price Change | -5.49% |
| Fifty-Two Week Price Change | -32.84% |
| Year-to-Date Price Change | -13.59% |
| Month-to-Date Price Change | -23.63% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.34149 USD |
| Book Value Per Share (Most Recent Quarter) | 1.99421 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.52562 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.31494 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.77212 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.33234 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.57543 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -6.47098 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.91983 USD |
| Normalized (Last Fiscal Year) | -6.47098 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -6.47098 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.91983 USD |
| Including Extraordinary Items (Last Fiscal Year) | -6.47098 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.91983 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 12.91747 USD |
| Cash Per Share (Most Recent Quarter) | 10.76978 USD |
| Cash Flow Per Share (Last Fiscal Year) | -6.22135 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -5.66164 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.29701 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -43 |
| Cash Flow Revenue (Trailing Twelve Months) | -399 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,011.03% |
| Pretax Margin (Last Fiscal Year) | -1,934.97% |
| Pretax Margin (5 Year) | -53.20% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 13.98% |
| Gross Margin (Trailing Twelve Months) | 4.26% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,785.46% |
| Operating Margin (Trailing Twelve Months) | -872.93% |
| Operating Margin (5 Year) | -52.38% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,947.09% |
| Net Profit Margin (Trailing Twelve Months) | -1,027.52% |
| Net Profit Margin (5 Year) | -51.35% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -2.02% |
| Tangible Book Value (5 Year) | -7.03% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 359.37% |
| Revenue Growth (3 Year) | 7.02% |
| Revenue Change (Trailing Twelve Months) | -75.25% |
| Revenue Per Share Growth | 0.97% |
| Revenue Growth (5 Year) | -24.97% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 11.00% |
| Total Debt (5 Year) | 69.48% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 19.43% |
| EPS Change (Trailing Twelve Months) | -50.13% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 19 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -5,983,000 |
| Net Debt (Last Fiscal Year) | -121,902,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 18 |
| Price to Sales (Trailing Twelve Months) | 10 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 5 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 3 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 239 |
| Long Term Debt to Equity (Most Recent Quarter) | 534 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 9 |
| Quick Ratio (Most Recent Quarter) | 7 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 9 |
| Current Ratio (Most Recent Quarter) | 7 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -153,083,000 |
| Free Cash Flow (Trailing Twelve Months) | -110,602,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -12 |
| Net Interest Coverage (Trailing Twelve Months) | -6 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 239 |
| Total Debt to Equity (Most Recent Quarter) | 534 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -40.15% |
| Return on Assets (Trailing Twelve Months) | -34.02% |
| Return on Assets (5 Year) | -12.43% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -90.24% |
| Return on Equity (Trailing Twelve Months) | -126.41% |
| Return on Equity (5 Year) | -19.37% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -44.48% |
| Return on Investment (Trailing Twelve Months) | -37.34% |
| Return on Investment (5 Year) | -13.46% |